Podcasts about datasets

Does size matter? When it comes to datasets, the conventional wisdom seems to be a resounding, "Yes!" But what about small datasets? Small- and mid-sized businesses and nonprofits, especially, often have limited web traffic, small email lists, CRM systems that can comfortably operate under the free tier, and lead and order counts that don't lend themselves to "big data" descriptors. Even large enterprises have scenarios where some datasets easily fit into Google Sheets with limited scrolling required. Should this data be dismissed out of hand, or should it be treated as what it is: potentially useful? Joe Domaleski from Country Fried Creative works with a lot of businesses that are operating in the small data world, and he was so intrigued by the potential of putting data to use on behalf of his clients that he's mid-way through getting a Master's degree in Analytics from Georgia Tech! He wrote a really useful article about the ins and outs of small data, so we brought him on for a discussion on the topic! This episode's Measurement Bite from show sponsor Recast is an explanation of synthetic controls and how they can be used as counterfactuals from Michael Kaminsky! For complete show notes, including links to items mentioned in this episode and a transcript of the show, visit the show page.

In this episode I discuss dataset-JSON, a new proposed data standard for CDISC files and explain some of the CDISC files I use in my clinical pharmacology work. I end with some brief thoughts about the ACoP 2025 meeting in Denver in October 2025.Links discussed in the show:CDISC dataset-JSON CDISC files I use You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

Featuring perspectives from Dr Carla Casulo and Dr Brad S Kahl: Introduction (0:00) Faculty Data and Case Presentation — Dr Kahl (6:38) Faculty Data and Case Presentation — Dr Casulo (25:38) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. CME information and select publications here.

The collected sources focus predominantly on the rapid adoption, legal risks, and regulatory challenges of Artificial Intelligence (AI) within the legal sector and beyond. Multiple texts emphasize the growing concern over algorithmic bias and discrimination in high-risk AI applications, particularly under new state laws like the Colorado Anti-Discrimination in AI Law, which places distinct compliance burdens on developers and deployers. A critical theme across several articles is the immediate risk of AI misuse by attorneys, detailing court sanctions and fines against lawyers in California, Alabama, and Maryland for submitting filings with fabricated or "hallucinated" legal citations. Furthermore, the documents explore broader legal battles concerning intellectual property and copyright infringement stemming from unauthorized data use in AI training, exemplified by disputes involving tech giants and media companies. Finally, the sources also cover the positive economic impact of legal AI tools, highlighting new startups securing significant funding to automate paralegal tasks and the critical need for law firms to develop robust, human-centered AI governance and security frameworks to mitigate rapidly emerging threats like data breaches and deepfakes.Can anyone really regulate the internet?2025-10-15 | Tech XploreKaufman Dolowich Receives Mansfield Certification from Diversity Lab for 7th Consecutive Year, Firm Recommits to Mansfield Certification for 2025-2026, 10-15-20252025-10-15 | Kaufman DolowichTop Five AI Tools for Lawyers: How Legal AI Is Reshaping Law Firms2025-10-15 | Legaltech on MediumBoards, Not Buzzwords: The Real Driver of Legal AI Adoption2025-10-15 | Legal Technology News - Legal IT Professionals | Everything legal technologyThe future of law firms2025-10-15 | Berwin Leighton PaisnerCalifornia Governor Vetoes Bill That Would Have Required Employers to Provide Notice of AI Use2025-10-15 | Ogletree DeakinsUK legal professionals embrace AI: how legal specific platforms are driving accuracy2025-10-14 | Legal FuturesNew Leaders Propel Lexitas into the Future of Legal Tech2025-10-14 | InvestorsHangout.comTransforming Legal Departments with AI: A Winning Strategy2025-10-14 | InvestorsHangout.comHow AI Is Changing Legal Education with Dyane O'Leary and Jonah Perlin2025-10-14 | GenAI-LexologyWhy Small Language Models Are the Future of Legal AI2025-10-14 | Legaltech on MediumPortolano Cavallo is the first Italian law firm to adopt Legora, a generative AI platform for law firms2025-10-14 | Legal Technology News - Legal IT Professionals | Everything legal technologyThe Inside View: Richard Miskella, co-managing partner of Lewis Silkin, discusses new AI employment tool Delphius2025-10-14 | Legal IT InsiderThe Library Innovation Lab at Harvard Law School Announces Launch of Data.gov Archive Search; Access to 311,000 Datasets (17.9 Terabytes of Data)2025-10-14 | Stephen's LighthouseIncredible Speakers at Legal Innovators UK – Nov 4, 5 and 62025-10-14 | Artificial LawyerArtificial Lawyer Is In Sweden, Back Mon, Oct 202025-10-14 | Artificial LawyerReducto Secures $75 Million Series B2025-10-14 | CooleyLeadership in the Age of AI: Lessons in Ethics, Compliance, and Governance2025-10-14 | Morris, Manning & Martin,LLPMeet Jason Kravitz: Cybersecurity & Privacy Practice Leader2025-10-14 | Nixon PeabodyCalifornia Governor Vetoes “No Robo Bosses Act” – What Employers Need to Know About Latest AI Workplace News2025-10-14 | Fisher & Phillips LLPBreaking Down the Intersection of Right-of-Publicity Law, AI2025-10-14 | Blank Rome

Is your AI built on quicksand? Learn how bad data, poisoned datasets, and deep fakes threaten your AI systems, and what to do about it.In this episode of CXOTalk (#896), AI luminaries Dr. David Bray and Dr. Anthony Scriffignano reveal the hidden dangers lurking in your AI foundations. They share practical strategies for building trustworthy AI systems and escaping the "AI quicksand" that traps countless organizations.

Mike & Tommy go through a great mailbag question on composite models and reusable models, along with how this changes in Fabric.Whoa! I think I'm triggered after listening to both your composite model episode and your managing multiple dataset episode. Isn't a fair bit of the question similar however much of the discussion seems different between episodes... In one sense- the gold standard seems to be thorough with data modeling/dataset development to build a dataset that can be used in multiple thin reports as needed. But the use of composite models seems to be somewhat discouraged - even though this is another way to re-use key datasets to answer business questions without re-doing the exact same transforms. It was alluded to but not explored that Fabric has better ways of doing this.With the data warehouse or Lakehouse... can you expand on that?Thanks for the podcast. Even though I consider myself skilled at Power BI - I'm constantly learning from you guys! Get in touch:Send in your questions or topics you want us to discuss by tweeting to @PowerBITips with the hashtag #empMailbag or submit on the PowerBI.tips Podcast Page.Visit PowerBI.tips: https://powerbi.tips/Watch the episodes live every Tuesday and Thursday morning at 730am CST on YouTube: https://www.youtube.com/powerbitipsSubscribe on Spotify: https://open.spotify.com/show/230fp78XmHHRXTiYICRLVvSubscribe on Apple: https://podcasts.apple.com/us/podcast/explicit-measures-podcast/id1568944083‎Check Out Community Jam: https://jam.powerbi.tipsFollow Mike: https://www.linkedin.com/in/michaelcarlo/Follow Seth: https://www.linkedin.com/in/seth-bauer/Follow Tommy: https://www.linkedin.com/in/tommypuglia/

Jim Rohn International Founder Kyle Wilson has an in-depth conversation with AI expert Natalie Contreraz. Natalie shares why now is the time to go all-in on AI! She shares: How to use AI as your mentor and in checking 5-year goals How to build while you sleep: automation, datasets, and the new content engine How to go from zero to omnipresent: turning your IP into a 24/7 marketing machine Her 3-step system to Collect → Organize → Publish How to make LinkedIn workflows; don't love camera? Use AI to help. How building an agency is the path to optionality, choice, and freedom Find Natalie Contreraz: IG: @nataliemeaagan Facebook: @Natalie Contreraz Kyle Wilson Resources: Kyle Wilson Website: KyleWilson.com Success Habits Podcast - Go to KyleWilson.com/podcast Kyle Wilson Inner Circle Mastermind https://kylewilson.com/mastermind/ Follow Kyle Wilson: Instagram: instagram.com/kylewilsonjimrohn Facebook: facebook.com/kylewilsonmarketing YouTube: youtube.com/KyleWilsonMarketing Twitter: twitter.com/kwmarketing What Others are Saying About Kyle “Kyle, thank you for our partnership and friendship. Friendship is wealth and you make me a rich man. Love and Respect!” Jim Rohn, Iconic Philosopher and Speaker  “I guard my endorsements carefully. Regarding Kyle, he is simply a marketing genius! No joke. Kyle was the wizard behind the successful business of my mentor Jim Rohn. Every marketing dilemma I have ever had Kyle has given me the brilliant and elegant solution on the spot. Kyle's consulting has saved and earned me hundreds of thousands of dollars over the years.” Darren Hardy, Former Publisher of SUCCESS Magazine "Kyle Wilson is brilliant and so very knowledgeable and an icon in this industry. He was the power behind Jim Rohn. Kyle is my longtime friend and someone I have a great deal of respect for." Les Brown, Iconic Speaker and Author “I have worked closely with Kyle Wilson for 20 years. He is one of the best all-around marketers, promoters, business-builders, and entrepreneurs in the business today. We have generated more than a million dollars together.” Brian Tracy, International Speaker and Author “Kyle is a valued friend, a marketing superstar and one of the most knowledgeable people in the personal development industry.” Robin Sharma, Author of, Monk Who Sold His Ferrari “I've known and worked with Kyle Wilson for over 20 years. Kyle is the ONLY person that ALWAYS under-promised and over-delivered every single time my dad Zig and I worked with him. He is a valued friend and someone I have great admiration and respect for!" Tom Ziglar, President of Zig Ziglar Corp “Kyle is one of my old and dear friends and one of the smartest marketing guys I have had the opportunity to work with. He is the scrappy marketing guy. What I mean by that is, there are lots of guys who will put out business plans and do all kinds of nonsense and swing for home runs. Kyle is the real deal and finds ways to create product, add value, help people, build community, he's unbelievable.” Eric Worre, Author of Go Pro "Kyle you were a master to work with when filming and producing at my house. Also, Helen and I have toured and done so many 'meet and greets' and have had all kinds of cool activities and opportunities on the road, but last year at your house at the Inner Circle Mastermind ranks at the top as one of the all-time best experiences we have ever had on the road. At your house the people and the love was so amazing. We are use to doing all the giving, but that day we felt loved and cared for. It was just an amazing experience! We still talk about it to this day. It is at the top of our tour memories from over all these years!" Phil Collen, Guitarist of Def Leppard, Songwriter, and Author "Thank you, Kyle Wilson, for being such a magnificent leader and creating a powerful, humanitarian thinking group of leaders. You're such an amazing human being. Always inspired by who you are!" Lisa Haisha, Amazon Show Host, Producer, and Philanthropist  "Kyle Wilson is the man! When I made the decision to transition from my 15-year MLB career to being a speaker, best-selling author, and business consultant I researched and then sought out the man who has been behind such iconic speakers as Jim Rohn, Brian Tracy, and many others. Hiring Kyle as my coach has been one of the smartest decisions I made." Todd Stottlemyre, Author of Rentless Success, 15-Year MLB Pitcher and 3x World Champion "Kyle is one of the wisest and most brilliant marketing consultants in the world. He is the man behind the great marketing of Jim Rohn International and so many other personal development legends. He is not only someone I've enjoyed collaborating and working with for over two decades, but also a close and valued friend. I recommend Kyle without equivocation." Mark Victor Hansen, Co-Creator of World's Best-Selling Book Series Chicken Soup for the Soul  "Kyle, you ROCKED the EOFIRE show. You are a great storyteller and shared great lessons. Truly impressed…and thank you for what you do/have done for this Entrepreneurial world." John Lee Dumas, Host of EOFIRE Podcast with over 100 million Downloads  "Kyle Wilson, single handedly changed the way I look at life! And the way I participate in my own! Kyle's wisdom, loyalty and commitment to seeing people soar is unmatched in the industry. He is a springboard, sounding board, and ultimately a launch pad for anyone committed to pursuing their deepest dreams and ultimate goals! He is the most authentic mentor, friend, and business partner I've ever had. I'm so thankful I ended up in your sphere 'KW' Kyle Wilson.” Erika De La Cruz, TV & Media Host, Speaker, Trainer, and Author of Passionistas "Kyle, you have greatly influenced my life and career. You and Jim made a perfect team with a legacy that will continue to change lives more than any other thought leaders with timeless wisdom." Denis Waitley, Author of The Psychology of Winning  "Anytime I'm in a conversation with Kyle Wilson, I always take my notepad out and start taking down notes cause there's so much to learn. Kyle it's a real honor for me to know you." Bob Burg, Speaker and Best-Selling Author of The Go Giver Subscribe, Rate & Review (plus bonuses) Please subscribe to the Success Habits podcast and leave an honest rating & review. This will encourage other people to listen and allow us to grow as a community. The bigger we get as a community, the bigger the impact we can have on the world. Once subscribed, send an email to podcast@kylewilson.com to receive over $200 in cool bonuses.  

Characterising the behaviour of drugs in humans has historically required extensive clinical trials at considerable time and cost. So, any lab-derived early insight into how drugs will behave in human patients can make drug trials vastly more efficient. In this episode, the pharmaphorum podcast welcomes Adityo Prakash, founder and CEO of Verseon, a clinical-stage pharmaceutical company based in Fremont, California that is developing several drug discovery programmes in cardiometabolic diseases and cancer using molecular physics and artificial intelligence. Prakash discusses development of new AI technologies to handle the small, sparse datasets typical of real-world scenarios, and how testing drugs on organoids – artificially grown masses of cells that resemble the function of specific human organs – can deliver valuable information on the potential effects of drugs in real patients before any human is dosed. You can also listen to episode 201a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Featuring perspectives from Dr Benjamin Levy, including the following topics: Introduction: The Boards (0:00) Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43) Immunotherapy for Metastatic NSCLC (24:41) Antibody-Drug Conjugates (33:46) Novel Bispecific Antibodies (42:08) Journal Club with Dr Levy (51:28) CME information and select publications

Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. CME information and select publications here.

Featuring perspectives from Prof Susana Banerjee and Dr Ursula Matulonis, including the following topics: Introduction: Tale of Two Cities — ASCO 2025 (0:00) Ovarian Cancer (11:20) HER2-Positive Gynecologic Cancers (31:28) Endometrial Cancer (40:16) Cervical Cancer (51:14) CME information and select publications

Prof Susana Banerjee from The Institute of Cancer Research in London and Dr Ursula Matulonis from Dana-Farber Cancer Institute in Boston discuss important efficacy and safety data from the past year related to the management of ovarian, endometrial and cervical cancers.CME information and select publications here.

Analyses that include low-quality MRI data underestimate cortical thickness and overestimate cortical surface area, according to new findings from the Adolescent Brain Cognitive Development (ABCD) Study.

Hans looks into the tactical archiving efforts of our nation's librarians, and Mike unboxes a bussin glow-up of an alt big mood to brainrot. Also: Ask an Expert!–Become a Never Post member at https://www.neverpo.st/ for access to extended and bonus segments, and our side shows.– Call us at 651 615 5007 to leave a voicemail Drop us a voice memo via airtable Or email us at theneverpost at gmail dot com –Intro Links Internet Archive Is Now a Federal Depository Library Google users are less likely to click on links when an AI summary appears in the results A Second Tea Breach Itch.io Suddenly Pulls NSFW Adult Content Update on NSFW content YouGov poll results European project Eurosky eurosky.social –Ask an Expert! Micah Loewinger Adopt-A-Station –Tactical Archiving Tracking Government Information Data Rescue Project UChicago Data Mirror Federal Data Forum America's Essential Data Internet Archive's Wayback Machine –Tralalero TralarotRyan: Garbage Day Panic World Emilie: ‘It speaks to me in brain rot' emilieowens.ca hf.uio.no –Never Post's producers are Audrey Evans, Georgia Hampton and The Mysterious Dr. Firstname Lastname. Our senior producer is Hans Buetow. Our executive producer is Jason Oberholtzer. The show's host is Mike Rugnetta.Never Post is a production of Charts & Leisure

Ryan Steelberg, CEO of Veritone (VERI), explains what the company does and why investors might be interested. Veritone provides AI computing solutions and services and just announced a contract with the Air Force. “We are experts in leveraging AI…against unstructured datasets.” He gives the example of data from body cameras that must be “ingested, indexed and understood” to help investigations. Another use is “automated redaction,” which he says can reduce costs by 30%-50%. “We have hundreds of customers across the U.S.” He sees a clear path to profitability ahead.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Welcome to Chat GPT, the only podcast where artificial intelligence takes the mic to explore the fascinating, fast-changing world of AI itself. From ethical dilemmas to mind-bending thought experiments, every episode is written and narrated by AI to help you decode the technology shaping our future. Whether you're a curious beginner or a seasoned techie, this is your front-row seat to the rise of intelligent machines—told from their perspective. Tune in for smart stories, surprising insights, and a glimpse into the future of thinking itself. Listen Ad Free https://www.solgoodmedia.com - Listen to hundreds of audiobooks, thousands of short stories, and ambient sounds all ad free!

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos and Dr Robert Z Orlowski, including the following topics: Introduction: ASCO 2025 Preview (0:00) Anti-CD38 Antibodies (10:12) Belantamab Mafodotin (29:45) CAR T-Cell Therapy (40:57) Bispecific Antibodies (47:33) Other Novel Agents (56:46) CME information and select publications

Prof Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Texas, provide their perspectives on relevant new clinical data in multiple myeloma and their application to disease treatment. CME information and select publications here.

Featuring perspectives from Prof Claire Harrison and Dr John Mascarenhas, including the following topics: Introduction (0:00) New Biology of Myelofibrosis (1:55) Novel Regulatory T-Cell Infusion Therapy (14:57) Myelofibrosis 2025: JAK Inhibitors (Ruxolitinib) (20:39) BET Inhibitors: Pelabresib (42:03) Navtemadlin (53:20) CME information and select publications

Professor Claire Harrison from the Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. CME information and select publications here.

Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics: Introduction: Actionable Genomic Alterations (0:00) ALK (9:49) ROS1 (22:22) HER2 (31:00) RET (38:52) NTRK (45:30) MET (46:31) Novel Targeted Strategies (49:09) BRAF (54:19) KRAS G12C (55:38) CME information and select publications

Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. CME information and select publications here.

Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics: Introduction: Bispecific Antibodies in Community Practice (0:00) Diffuse Large B-Cell Lymphoma (7:06) CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15) Mantle Cell Lymphoma (32:36) Follicular Lymphoma (48:08) CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17) CME information and select publications

Dr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. CME information and select publications here.

Featuring perspectives from Dr Ian E Krop and Dr Sara M Tolaney, including the following topics: Introduction: Adjuvant CDK4/6 Inhibition (0:00) HER2-Positive Disease (11:13) PARP Inhibition (27:34) Antibody-Drug Conjugates (34:12) Up-Front Treatment of HR-Positive Metastatic Disease (46:28) CME information and select publications

Dr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. CME information and select publications here.

Featuring perspectives from Dr Emmanuel S Antonarakis and Prof Karim Fizazi, including the following topics: Introduction: Quality of Life (0:00) PARP Inhibition (PARPi) (7:15) M0 Disease (23:18) Metastatic Hormone-Sensitive Prostate Cancer (34:33) Radiopharmaceuticals (46:16) Other Novel Investigational Approaches for Metastatic Castration-Resistant Prostate Cancer (54:53) CME information and select publications

Dr Emmanuel S Antonarakis from the University of Minnesota in Minneapolis and Professor Karim Fizazi from the Institut Gustave Roussy in Villejuif, France, provide their perspectives on relevant new clinical data in prostate cancer and discuss their application to the care of patients. CME information and select publications here.

Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics: Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00) CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06) Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative Breast Cancer (21:17) Treatment of PIK3CA/PTEN/AKT-Mutated Breast Cancer (31:34) Antibody-Drug Conjugates (ADCs) for HR-Positive, HER2-Negative Breast Cancer (38:41) ADCs for HER2-Positive Breast Cancer (46:30) HER2-Targeting Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer (53:26) ADCs for Advanced Triple-Negative Breast Cancer (58:29) CME information and select publications

Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers. CME information and select publications here.

Featuring perspectives from Dr Jennifer R Brown and Prof Paolo Ghia, including the following topics: Introduction: The Chronic Lymphocytic Leukemia (CLL) Experience — 2000 to 2025 (0:00) Current Therapy Options with Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (9:42) Role of Venetoclax in the Treatment of CLL (26:52) AMPLIFY Trial and Other Novel BTK Inhibitor and Bcl-2 Inhibitor Combination Strategies (32:29) Noncovalent BTK Inhibitor Pirtobrutinib (46:47) CAR T-Cell Therapy; Novel Agents (56:12) CME information and select publications

Dr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. CME information and select publications here.

In this episode, Elizabeth chats with Dr. Kendrick Kay, an Associate Professor in Radiology at University of Minnesota, Twin Cities. He directs the Computational Visual Neuroscience Laboratory, and aims to understand brain function by combining cognitive neuroscience, functional MRI methods, and computational neuroscience. In this episode, Kendrick shares his work on the groundbreaking Natural Scene Dataset and discusses the behind-the-scenes considerations that went into its creation. He also outlines important points for brain scientists to think about when creating and using large-scale fMRI datasets, and shares parts of his journey as a scientist.Discussed Papers in Podcast: A massive 7T fMRI dataset to bridge cognitive neuroscience and artificial intelligencePrinciples of intensive human neuroimagingKendrick's website: http://cvnlab.netElizabeth's: website: imelizabeth.github.ioElizabeth's BlueSky: @imelizabeth.bsky.socialPodcast BlueSky @StanfordPsyPod.bsky.socialPodcast Twitter @StanfordPsyPodPodcast Substack https://stanfordpsypod.substack.com/Let us know what you thought of this episode, or of the podcast! :) stanfordpsychpodcast@gmail.com

Unveiling bioanalytical datasets for the successful development of ADCs

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston and Dr Jeffrey Meyerhardt from Dana-Farber Cancer Institute in Boston summarize the most clinically relevant research findings and data presented over the past year for patients with colorectal cancer. CME information and select publications here.

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston and Dr Jeffrey Meyerhardt from Dana-Farber Cancer Institute in Boston summarize the most clinically relevant research findings and data presented over the past year for patients with colorectal cancer. CME information and select publications here.

Featuring perspectives from Dr Scott Kopetz and Dr Jeffrey Meyerhardt, including the following topics: Introduction (0:00) Cell-Free DNA Molecular Residual Disease Assays in Clinical Practice (3:25) Immunotherapy for Localized and Metastatic Microsatellite Instability-High Colorectal Cancer (28:27) Other Important Datasets (46:06) CME information and select publications

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston and Dr Jeffrey Meyerhardt from Dana-Farber Cancer Institute in Boston summarize the most clinically relevant research findings and data presented over the past year for patients with colorectal cancer. CME information and select publications here.

Mike & Tommy go through a question from our mailbag on how to manage multiple datasets in Power BI. Get in touch:Send in your questions or topics you want us to discuss by tweeting to @PowerBITips with the hashtag #empMailbag or submit on the PowerBI.tips Podcast Page.Visit PowerBI.tips: https://powerbi.tips/Watch the episodes live every Tuesday and Thursday morning at 730am CST on YouTube: https://www.youtube.com/powerbitipsSubscribe on Spotify: https://open.spotify.com/show/230fp78XmHHRXTiYICRLVvSubscribe on Apple: https://podcasts.apple.com/us/podcast/explicit-measures-podcast/id1568944083‎Check Out Community Jam: https://jam.powerbi.tipsFollow Mike: https://www.linkedin.com/in/michaelcarlo/Follow Seth: https://www.linkedin.com/in/seth-bauer/Follow Tommy: https://www.linkedin.com/in/tommypuglia/

#airtable #on2air #builtonair 2/18/2025 - BuiltOnAir Live Podcast Full Show - S21-E07 ___________________________ The BuiltOnAir podcast is a live weekly show highlighting everything happening in the Airtable universe. Check us out at BuiltOnAir.com/join. Join our community, join our Slack channel, and see what's happening. ------------------------ SPONSORED BY On2Air - Airtable Apps and Integrations to run your business operations in Airtable Start a free 14-day trial of On2Air Apps - https://on2air.com?via=podcast ------------------------ ___________________________ IN THIS EPISODE

Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Disease (2:34) Adjuvant and Neoadjuvant Therapy (22:31) EGFR Exon 20 Insertion Mutations (34:21) Antibody-Drug Conjugates (42:45) CME information and select publications

Dr Enriqueta Felip from the Vall d'Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here

Dr Enriqueta Felip from the Vall d'Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here

In this episode of Two Bees in a Podcast, released on December 3, 2024, Dr. Jamie Ellis and Amy Vu welcome Dr. Mohamed Alburaki—a research entomologist at the Bee Research Laboratory with the USDA ARS in Beltsville, Maryland—to talk about his publishing(s) on the status report of honey bee diseases in the United States from 2015-2022. This episode concludes with a Q&A segment. Check out our website: www.ufhoneybee.com, for additional resources from today's episode. 

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Current Therapeutic Approaches for Multiple Myeloma — Dr Lonial (0:37) Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Raje (22:53) CME information and select publications

►Where do pollsters get their participants? ►Do election polling methods and target audiences change as we get closer to Election Day? ►Do Americans vote for candidates who match their values and positions? Or do we vote for candidates with the best campaigns? ►Are there tried-and-true election polling methods? ►Do polls influence election outcomes? ►How frequently have polls completely botched their predictions? ►What is my guest's prediction for this election? *****

What if the key to unlocking AI's full potential lies not just in algorithms or compute, but in data? In this episode, a16z General Partner David George sits down with Alex Wang, founder and CEO of Scale AI, to discuss the crucial role of "frontier data" in advancing artificial intelligence. From fueling breakthroughs with complex datasets to navigating the challenges of scaling AI models, Alex shares his insights on the current state of the industry and his forecast on the road to AGI. Resources: Find Alex on Twitter: https://x.com/alexandr_wangFind David on Twitter : https://x.com/DavidGeorge83 Stay Updated: Let us know what you think: https://ratethispodcast.com/a16zFind a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.